1.42
+0.03(+2.16%)
Currency In USD
| Previous Close | 1.39 |
| Open | 1.38 |
| Day High | 1.54 |
| Day Low | 1.3 |
| 52-Week High | 19.44 |
| 52-Week Low | 0.97 |
| Volume | 321,555 |
| Average Volume | 120,769 |
| Market Cap | 7.9M |
| PE | -0.05 |
| EPS | -27.2 |
| Moving Average 50 Days | 1.75 |
| Moving Average 200 Days | 5.11 |
| Change | 0.03 |
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respi
Traws Pharma Announces Management Updates
GlobeNewswire Inc.
Mar 28, 2025 8:30 PM GMT
Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “T
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
GlobeNewswire Inc.
Mar 26, 2025 11:30 AM GMT
Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird FluRatutrelvir, a main protease inhibitor, to be used without ritonavir,